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Abstract
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Introduction: The extraction of salient information from the environment is impaired by the
activation of dopamine receptors. Using rodent models, we previously reported that this perceptual
deficit, as measured by the prepulse inhibition (PPI) of startle, is effectively opposed by inhibitors
of the steroidogenic enzyme 5α-reductase (5αR). The specific 5αR isoenzyme and steroids
implicated in these effects, however, remain unknown.
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Methods: The effects of the selective D1 dopamine receptor agonist SKF-82958 (SKF, 0.3
mg/kg, IP) and D2 receptor agonist quinpirole (QUIN, 0.5 mg/kg, IP) were tested in the startle
reflex and PPI of knockout (KO) mice for either 5αR type 1 (5αR1) or type 2 (5αR2).
Furthermore, we established whether these effects may be modified by the 5α-reduced steroids
dihydroprogesterone (DHP), allopregnanolone (AP), dihydrotestosterone (DHT), 5αandrostane-3α,17β-diol (3α-diol), or androsterone. To test the mechanisms whereby 5αR products
may alter the PPI-disrupting properties of D1 agonists, we studied the involvement of GABA-A
and PXR, two receptors targeted by neuroactive steroids. Specifically, we tested the effects of SKF
in combination with the GABA-A antagonist bicuculline, as well as in KO mice for the GABA-A
δ subunit and PXR.
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Results: 5αR1, but not 5αR2 knockout (KO) mice, were insensitive to the PPI-disrupting effects
of SKF. This sensitivity was reinstated by AP (3 mg/kg, IP), but not other 5α-reduced steroids.
The PPI deficits induced by SKF were not modified by bicuculline, δ-subunit KO mice and PXR
KO mice.
Conclusions: These results collectively suggest that 5αR1 enables the negative effects of D1
dopamine receptor activation on information processing via production of AP. The contribution of
AP to the PPI-disrupting mechanisms of D1 receptor agonists, however, do not appear to be
mediated by either GABA-A or PXR receptors.
Keywords
Allopregnanolone; dopamine; sensorimotor gating; D1 receptors; 5α-reductase; behavioral studies
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1.

INTRODUCTION
The efficiency of information processing is contingent on the ability to filter out irrelevant
stimuli. Impairments of this function – termed sensorimotor gating - have been observed
across a broad range of neuropsychiatric conditions, including schizophrenia, obsessivecompulsive disorder (OCD) and Tourette syndrome (TS) (Geyer et al., 2006). The bestvalidated operational index to measure sensorimotor gating integrity in humans and animal
models is the prepulse inhibition (PPI) of the acoustic startle reflex, a cross-species
phenotype corresponding to the reduction of the startle response following a weak prestimulus (Hoffman and Ison, 1980).
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Due to its high cross-species translational validity, PPI has been extensively used in rodent
models to screen putative antipsychotic agents and investigate the molecular and
neurobiological underpinnings of schizophrenia and other gating disorders. A widely used
rodent model to screen antipsychotic efficacy is based on PPI deficits induced by
dopaminergic agonists (Geyer et al., 2001). In most mouse strains, D1-like receptor agonists
disrupt PPI in an antipsychotic-sensitive fashion (Ralph-Williams et al., 2003); conversely,
the effects of selective D2 receptor agonists are generally poor in this species, with the only
exception of a few strains (Ralph and Caine, 2005).
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Our group has shown that the PPI deficits induced by dopaminergic agonists is blocked by
inhibitors of 5α-reductase (5αR) (Bortolato et al., 2008). This family of steroidogenic
enzymes catalyze the saturation of the 4,5-double bond of the A ring of Δ4-3-ketosteroid
substrates, including progesterone, androstenedione, and testosterone (Paba et al., 2011).
This reaction leads to the synthesis of 5α-dihydrosteroids, including dihydroprogesterone
(DHP), androstanedione (ASD), and dihydrotestosterone (DHT). In turn, these steroids are
metabolized by 3α-hydroxysteroid oxidoreductase (3α HSOR) into 5α-pregnan-3α-ol-20one (allopregnanolone; AP), 5α-androstan-3α-ol-17-one (androsterone), and 5αandrostane-3α,17β-diol (3α-diol) (Paba et al., 2011). Although the two main 5αR
isoenzymes, termed 1 (5αR1) and 2 (5αR2), serve overlapping functional roles, they diverge
with respect to several key characteristics, including localization throughout the organism,
substrate affinity and pH optima (Paba et al., 2011).
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We recently documented that, in mice and rats, the antipsychotic-like effects of the
prototypical 5αR inhibitor finasteride is based on the opposition of the PPI-disrupting
effects of D1 receptor agonists (Frau et al., 2013; 2016). However, as finasteride is not
isoenzyme-specific in rodents (Thigpen and Russell, 1992), the specific implication of 5αR1
and 5αR2 with respect to the dopaminergic modulation of PPI remains elusive. Capitalizing
on these premises, we aimed the present study at studying which 5αR isoenzyme is directly
implicated in the modulation of dopaminergic responses in PPI, by testing the effects of D1and D2-like receptor agonists in 5αR1 and 5αR2 knockout (KO) mice. Furthermore, we
examined the specific steroid-based mechanisms involved in the observed mechanisms, by
testing whether the effects of 5αR inactivation on PPI were reversed by the implementation
of different 5αR products, including 5α-dihydro- and 3α,5α-tetrahydro steroids.

2.
Author Manuscript

2.1.

MATERIALS AND METHODS
Animals.
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The experiments included in this study were performed on adult (3-month old) male mice.
The following mutant lines were used: 5αR1, 5αR2, GABA-A subunit δ, and pregnane X
receptor (PXR) knockout (KO). These mice and their wild-type (WT) littermates were
generated by mating heterozygous sires and dams. Both 5αR1 and 5αR2 KO mouse
progenitors were a kind donation from Dr. Mala Mahendroo (Southwestern University).
Unless stated otherwise for specific experimental purposes, all mice were housed in groups
of 4–5/cage, with at least 1 mouse/genotype, and had ad libitum access to food and water.
Housing facilities were maintained at 22°C with a 12 h light/dark cycle (lights on at 06:00
AM hours and on at 06:00 PM). Experimental manipulations were carried out in the
animals’ light cycle between 8:00 AM and 4:00 PM. All handling and experimental
procedures were performed in compliance with the National Institute of Health guidelines
and approved by the local Institutional Animal Care and Use Committees. To avoid potential
confounds due to carry-over effects, each mouse was only used once throughout the study,
with the only exception of the experiments aimed at assessing the behavioral effects of 3αdiol and androsterone in combination with SKF, for which animals were tested in
counterbalanced order. Group sizes were defined based on power analyses run on
preliminary studies.
2.2.

Genotyping.
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Mouse genotyping was performed by PCR. Samples of genomic DNA were extracted from
tail biopsies acquired from mice at weaning (postnatal day 21). The following primers were
used to identify 5αR1 KO mice: 1) GAT TGG GAA GAC AAT AGC AGG CAT GC 2)
CCA GAC ACG AAC TTC CAC GCT TCT G 3) ATG GAG TTG GAT GAG TTG TGC.
Reaction conditions were: 94°C × 1.5 min, 94°C × 20s, 55°C × 30s, 72°C × 2 min, 4°C ×
∞, as previously described (Mahendroo et al., 2001). The following primers were used to
identify 5αR2 KO mice: 1) GAT GAC CTC TCC GGG CTT CC 2) GAA TGT TCC AAG
TCA CAG GC 3) CGC TTC TGA GGA GAG AAC TGA CTG A. Reaction conditions
were: 94°C × 2 min, 94°C × 40s, 55°C × 40s, 72°C × 5 min, 4°C × ∞, as previously
described (Mahendroo et al., 2001). The following primers were used to identify δ KO mice:
1) GCA GGC TGT CCT ACA ACC AT; 2) ATG CCA CTC CTG ATG CCT AC; 3) GGG
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GTT TGC TCG ACA TTG. Reaction conditions were: 94°C × 2 min, 94°C × 20s, 65°C ×
15s, 68°C × 10s. The following primers were used to identify PXR KO: 1) CTG GTC ATC
ACT GTT GCT GTA CCA; 2) GCA GCA TAG GAC AAG TTA TTC TAG AG; 3) CTA
AAG CGC ATG CTC CAG ACT GC. Reaction conditions were: 95°C × 3 min, 95°C × 45s,
60°C × 30s, 72°C × 60s.
2.3.

Drugs.
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The following drugs were used in this study: the D1 receptor agonist SKF-82958 (SKF;
Sigma Aldrich, St. Louis, MO, USA; 0.3 mg/kg, IP; 10 min before behavioral testing); the
D2 receptor agonist quinpirole (QUIN) (Sigma Aldrich; 0.5 mg/kg, IP; 15 min before
testing); the GABA-A receptor bicuculline (Sigma Aldrich; 1 mg/kg, IP; 15 min before
testing); DHP (Sigma Aldrich; 3–10 mg/kg, IP; 15 min before testing); AP (Tocris
Bioscience, Bristol, UK; 1–3 mg/kg, IP; 30 min before testing); DHT (Sigma; 3 mg/kg, IP;
15 min before testing); 3α-diol (Tocris; 3 mg/kg, IP; 15 min before testing); and
androsterone (Tocris; 3 mg/kg, IP; 15 min before testing). SKF and QUIN were dissolved in
saline. Bicuculline was dissolved in saline with few drops of concentrated acetic acid. DHP,
AP, DHT, androsterone, and 3α-diol were dissolved in 2% DMSO, 3% Tween 80 and saline.
Doses were based on previous studies on the effects of these compounds in PPI in mice
(Yeomans et al., 2010; Frau et al., 2016) as well as pilot studies on the behavioral effects of
steroids.
2.4.

Acoustic startle reflex and PPI.

Author Manuscript
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Startle testing was conducted as previously described (Godar et al., 2016). Briefly, the
apparatus used for detection of startle reflexes (SR-LAB; San Diego Instruments, San Diego,
CA, USA) consisted of five Plexiglas cages (diameter: 5 cm) in sound attenuated chambers
with fan ventilation. Each cage was mounted on a piezoelectric accelerometric platform
connected to an analogue digital converter. The response to each stimulus was recorded as
65 consecutive 1 ms readings. A dynamic calibration system was used to ensure comparable
sensitivities across chambers. The startle testing protocol featured a 70-dB background white
noise, and consisted of a 5 min acclimatization period, followed by three consecutive blocks
of pulse, prepulse + pulse and ‘no stimulus’ trials. During the first and the third block, mice
received only five pulse-alone trials of 115 dB. Conversely, in the second block mice were
exposed to a pseudorandom sequence of 50 trials, consisting of 12 pulse-alone trials, 30
trials of pulse preceded by 73, 76 or 82 dB pre-pulses intensities (10 for each level of
prepulse loudness) and eight no stimulus trials, where only the background noise was
delivered. Intertrial intervals were selected randomly between 10 and 15 s. Sound levels
were assessed using an A-scale setting. Percent PPI was calculated with the following
formula:
100 −

mean startle amplitude f or prepulse pulse trials
× 100
mean startle amplitude f or pulse alone trials

The first five pulse-alone bursts were excluded from the calculation. As no interactions
between prepulse levels and treatment were found in the statistical analysis, %PPI values
were collapsed across prepulse intensity to represent average %PPI.
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Locomotor behaviors were measured in a square force-plate actometer (28cm × 28cm) as
previously described (Fowler et al., 2001). In brief, mice (n=8/genotype) were placed in the
center and their behavior was monitored for 20 min for the baseline locomotor activity
studies. In a subsequent study 5αR1 KO, HZ, and WT mice (n=8/genotype) were placed in
the center and their behavior was monitored for 60 min before they were removed, treated
with SKF, QUIN or vehicle and placed back into the actometer for an additional 120 min.
Each force plate actometer consisted of four force transducers placed at the corners of each
load plate. Transducers were sampled 100 times s−1, yielding a 0.01 s temporal resolution, a
0.2 g force resolution and a 2-mm spatial resolution. Custom software directed the timing
and data-logging processes via a LabMaster interface (Scientific Solutions Inc., Mentor, OH,
USA). Distance travelled was calculated as the sum of the distances between coordinates of
the location of center of force recorded every 0.50 s over the recording session.
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2.6.

Statistical Analyses.
Data were tested for normality by the Kolmogorov-Smirnov test. Parametric statistical
analyses were performed by multiway ANOVAs, followed by Tukey’s test for post-hoc
comparisons. Significance was set at P = 0.05.

3.

RESULTS

3.1. Genetic 5αR1 deficiency renders mice insensitive to the PPI-disruptive effects of D1
receptor activation.
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We first analyzed the effects of SKF (0.3 mg/kg, SC) on startle amplitude and PPI in 5αR1
KO and HZ mice, as compared to WT littermates (n=12/group). As described in Fig. 1A,
WT mice exhibited higher startle values [Main effect for genotype: F(2,66)=8.00, P=0.0008]
than HZ (P=0.02) and KO (P=0.0008; Tukey’s). However, SKF did not modify this
parameter in either genotype. The analyses of PPI values (Fig. 1B) revealed that SKF
reduced PPI in WT [genotype x treatment interaction: F(2,66) = 5.47, P=0.006; SKF vs
vehicle: P=0.0003; Tukey’s), but not in either HZ or KO mice. The effects of SKF were
significantly greater in WT mice than their HZ (P=0.03) and KO littermates (P=0.0003).
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We then analyzed the effects of the D2 receptor agonist QUIN in 5αR1-deficient mice
(n=12–14/group). Startle amplitude was reduced by both 5αR1 deficiency [Main effect of
genotype: F(2,74) = 15.59, P < 0.0001; WT vs HZ: P=0.0009; WT vs KO: P=0.0001,
Tukey’s] (Fig. 1C) and QUIN [Main effect of treatment: F(1,74) = 6.65, P = 0.01]. However,
no interaction between these two factors was found. PPI analyses (Fig. 1D) surprisingly
revealed that QUIN lowered PPI levels in KO mice [Genotype x treatment interaction:
F(2,74)=3.48, P=0.04; QUIN- vs saline- treated KO mice: P=0.001; Tukey’s], but not in WT
(QUIN-treated WT vs QUIN-treated KO: P=0.0002) or HZ (QUIN-treated HZ vs QUINtreated KO: P=0.004) counterparts.
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3.2. Genetic 5αR1 deficiency does not alter the locomotor effects of D1 or D2 receptor
activation.
We next tested the locomotor effects of D1 and D2 receptor agonists on 5αR1 KO mice (Fig
2). As expected, the D1 receptor agonist SKF increased locomotor activity in both WT and
KO mice for the 90-min period following injection (Fig 2A) [treatment x time interaction:
F(12,624)=32.04, P<0.0001; Ps<0.001 for all comparisons with 0’; Tukey’s]. The locomotor
effects of SKF, however, were comparable across genotypes. In contrast with SKF, QUIN
was found to significantly reduce locomotor activity in both genotypes [treatment x time
interaction: F(12,552)=3.69, P<0.0001]. In addition, unlike WT mice, KO littermates
exhibited a significant hypolocomotor response of QUIN in the 10-min bin after injection
[genotype x treatment x time interaction: F(24,552)=1.91, P=0.006; P=0.0001 for WT vs KO
mice; Tukey’s]
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3.3. Genetic 5αR2 deficiency does not alter the sensitivity of mice to the PPI-disruptive
effects of D1 receptor activation.
Contrary to our findings on 5αR1 KO mice, SKF did not affect startle amplitude in 5αR2deficient mice (n=8/group; Fig. 3A); furthermore, 5αR2 KO and HZ mice were equally
sensitive as their WT littermates to the PPI-disrupting effects of SKF (Fig 3B) [Main effect
of treatment: F(1,41) = 38.19, P < 0.001]. Conversely, QUIN elicited a statistical trend
towards a significant reduction in startle amplitude in 5αR2 KO mice and their littermates
[Main effect of treatment (F(1,53) = 3.52, P = 0.08) (Fig. 3C)] (n=9–10/group); however,
this drug did not elicit any significant PPI alterations in any genotype (Fig. 3D).
3.4. The insensitivity of 5αR1 KO mice to the PPI-disrupting effects of the D1 receptor
agonist is restored by AP, but not by DHP.

Author Manuscript
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We next tested whether the effects of 5αR1 deficiency on the PPI-disrupting properties of
SKF could be reversed by administration of two of its pregnane products, namely DHP and
its metabolite AP. Analyses were run by 3-way ANOVAs, with genotype, steroid treatment,
and SKF as factors. In conformity with our previous results, the analysis of the effects of
DHP (3 mg/kg, IP) (Fig. 4A) showed that KO mice exhibited lower startle values than those
of WT [main effect of genotype: F(1,84)=17.08, P= 0.0001]. As expected, SKF significantly
reduced PPI (Figs. 4B) in WT, but not KO mice [genotype x SKF interactions: DHP:
F(1,84)=29.35, P= 0.00001; Ps<0.001 for comparison between SKF-treated KO and vehicletreated KO as well as SKF-treated WT; Tukey’s test]; however, DHP did not modify the
effects of SKF in either WT or KO mice. The analysis of the effects of AP on startle
magnitude (Fig. 4C) revealed that SKF-treated WT mice exhibited an increased startle
amplitude in comparison with both vehicle-treated WT and SKF-treated KO mice [genotype
x SKF interaction: F(1,132)=13.60, P=0.0003; Ps =0.0008; Tukey’s test]. Furthermore, the
combination of SKF and the 3 mg/kg of AP produced a significant enhancement of startle
magnitude in comparison with each of all other treatment combinations [AP x SKF
interaction: F(2,132)=5.77, P=0.004; Ps<0.001, Tukey’s test], irrespective of genotypes. As
expected, the combination of SKF and vehicle in KO mice failed to cause PPI deficits, but
the dose of 3 mg/kg of AP restored the sensitivity of these animals to the PPI-disrupting
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effects of SKF [genotype x AP x SKF interaction: F(2,132)=5.00, P=0.008; P=0.0002 for
comparison between SKF-treated KO mice treated with AP or its vehicle; Fig. 4D].
3.5. Androgen products of 5αR1 do not reinstate the PPI-disrupting effect of D1 receptor
agonists in 5αR1 KO mice.
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We next tested whether the effects of 5αR1 deficiency on the PPI-disrupting properties of
SKF could be prevented by administration of 5α-reduced androgens, including DHT,
androsterone, and 3α-diol. Analyses were run by 3-way ANOVAs, with genotype, steroid,
and SKF treatments as factors. The analysis of the effects of DHT (3 mg/kg, IP) (Fig. 5A),
3α-diol (3 mg/kg, IP) (Fig. 5C), and androsterone (3 mg/kg, IP) (Fig. 5E) on startle
magnitude showed a significant reduction in startle values in KO mice, as compared with
their WT littermates [Main genotype effect: DHT: F(1,88)=57.00, P<0.0001; 3α-diol:
F(1,88)=171.45, P<0.0001; androsterone: F(1,88)=63.32, P<0.0001]. As expected, SKF
significantly reduced PPI (Figs. 5B, 5D, and 5F) in WT, but not KO mice [genotype x SKF
interactions: DHT: F(1,88)= 159.65 P<0.0001; 3α-diol: F(1,88)=79.43, P<0.0001;
Androsterone: F(1,88)=121.98, P<0.0001; Ps<0.001 for comparisons between SKF-treated
KO and WT, Tukey’s test]; however, the PPI disruption induced by the D1 receptor agonist
was not modified by any of these steroids.
3.6. The sensitivity to the PPI-disrupting effects of D1 receptor activation is not
moderated by either GABA-A or PXR.
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Given that our results indicated that AP enables D1-mediated PPI disruption, we next tested
whether the latter may be moderated by two of the best-characterized molecular targets
implicated in the function of this neurosteroid, GABA-A and PXR receptors. We first began
testing the effects of the GABA-A receptor bicuculline (1 mg/kg, IP; n=8–10/group) on the
startle effects of SKF in mice (Fig. 6A–B). The analysis of PPI values showed that SKF
reduced this index [Main effect of treatment: F(1,32)=24.16, P=0.0001] (Fig. 6B), but this
effect was not affected by bicuculline.
We then tested the effects of SKF in δ KO mice (Fig. 6C–D) (n=10–13/ group), Unlike our
previous results, SKF (0.3 mg/kg, IP) significantly enhanced startle [Main effect of
treatment: F(1,41)=5.03, P=0.03], likely reflecting differences in genetic background. PPI
was reduced by both KO [Main effect of genotype: F(1,41)=5.18, P=0.03] and SKF [Main
effect of treatment: F(1,41)=9.50, P=0.003]; however, no interactions between these two
factors were found.
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The analysis of the effects of SKF (0.3 mg/kg, IP) in PXR KO mice (Fig. 6E–F) (n=13–15/
group) showed that this drug increased startle amplitude in both genotypes [F(1,51)=4.09,
P=0.04]. The analysis of PPI showed that SKF significantly disrupted PP [F(1,51)=33.46,
P<0.0001], irrespective of genotypes, suggesting no involvement of PXR in this effect.

4.

DISCUSSION
The results of this study document that 5αR1 genetic deficiency renders mice insensitive to
the sensorimotor gating deficits, but not hyperactivity, induced by the potent dopamine D1
receptor agonist SKF. These findings complement previous data from our group on the
Psychoneuroendocrinology. Author manuscript; available in PMC 2020 October 01.
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ability of non-selective 5αR inhibitors, such as finasteride, to counter the PPI reduction
induced by D1 receptor activation in both mice and rats, without producing specific effects
on locomotor activity (Frau et al., 2013; 2016). Furthermore, we found that, in substantial
agreement with our previous data on finasteride (Bortolato et al., 2008; Frau et al., 2016),
5αR1 deficiency produced a significant decrement in startle magnitude without affecting
baseline PPI values, pointing to a role of this enzyme in the modulation of acoustic startle
exerted by several neuroactive steroids.
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Our findings also highlighted that 5αR1 KO mice are sensitive to the PPI-disrupting effects
of the D2 receptor agonist QUIN. In alignment with these results, previous data from our
group showed that finasteride also renders mice sensitive to PPI deficits induced by QUIN
(Frau et al., 2013). Taken together, these results suggest that changes in neuroactive steroid
profiles may be critical to modulate the sensitivity to the activation of either D1 or D2
receptors with respect to sensorimotor gating. As previous studies have shown that the
genetic background plays a critical role in defining the sensitivity of rats and mice to
dopaminergic agonists (Swerdlow et al., 2000; 2002; Ralph and Caine, 2005; Mosher et al.,
2016), these data raise the interesting question as to whether variations in gene expression of
5αR1 or other key neurosteroidogenic enzymes may contribute to interindividual differences
in the sensitivity to D1 and D2 receptor activation with respect to startle modulation.
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In contrast with 5αR1 KO mice, 5αR2-deficient animals were not found to exhibit
alterations in startle reflex, PPI values, or their dopaminergic modulation. These data
confirm previous findings on the lack of startle and PPI modifications in 5αR2 KO mice
(Mosher et al., 2018). Furthermore, they point to a functional divergence between 5αR
isoenzymes with respect to the modulation of dopaminergic neurotransmission, as well as
perception and information processing. While both 5αR1 and 5αR2 are predicted to serve
overlapping enzymatic functions, they diverge with respect to substrate affinity as well as
brain distribution pattern (Paba et al., 2011; Castelli et al., 2013). The selective role of 5αR1
in the responsiveness of mice to D1 receptor agonists in PPI may particularly reflect the
predominance of this isoenzyme in the brain (Normington and Russell, 1992). From this
perspective, it is worth noting that our previous results pointed to a key role of the medial
prefrontal cortex and the nucleus accumbens – two regions with abundant expression of
5αR1 - in the PPI-ameliorating effects of finasteride (Devoto et al., 2012).
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Another major finding of this study was that acute treatment with AP, but not other 5αreduced steroids (including DHP, DHT, 3α-diol, and androsterone) restored the sensitivity of
5αR1 KO mice to the PPI-disrupting effects of SKF. This finding is in line with recent
findings from our group, indicating that AP triggers PPI deficits in mouse models of TS
(Mosher et al. 2017) and sleep-deprived rats (Frau et al., 2018). Given the well-known role
of 5αR1 in the regulation of the biosynthetic pathway of AP, these data suggest that the
inactivation of this enzyme may impair the synthesis of AP in the brain. The baseline AP
brain and plasma levels of 5αR1 KO mice have been shown to be equivalent to that of their
WT counterparts (Osborne and Frye, 2009; Koonce and Frye, 2013; Tanchuck-Nipper et al.,
2015). However, specific brain-regional differences in baseline AP levels may occur
between WT and KO mice; alternatively, 5αR1 KO mice may exhibit an impaired synthesis
of AP in response to startle-associated stress and/or activation of D1 receptors. Accordingly,
Psychoneuroendocrinology. Author manuscript; available in PMC 2020 October 01.
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these mutants display a deficit in the conversion of progesterone into AP (Koonce and Frye,
2003). Unfortunately, as the limited small size of mouse brain regions represent a key
limitation for steroid detection, our analyses in the present study did not include the
measurement of AP levels. Future analyses, however, are warranted to verify whether brainregional steroid profiles can be modified by either D1 receptor activation or startle testing.
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Our next experimental step focused on the identification of the molecular mechanisms
whereby AP enables susceptibility to D1 receptor-mediated PPI disruption. The bestcharacterized receptor of AP is GABA-A, although its mechanisms of interaction with this
neurosteroid remain partially elusive. AP is a positive allosteric modulator of this receptor
(Majewska et al., 1986; Paul and Purdy, 1992; Rupprecht, 2003), even though this steroid
may also act as its agonist at micromolar concentrations (Belelli and Lambert, 2005). Recent
evidence points to the presence of two distinct AP-binding sites within the GABA-A
receptor, which are posited to be localized in the α subunit and the interface between α and
β subunits, respectively (Hosie et al., 2006; 2009). However, the actions of AP on GABA-A
receptors have been shown to be influenced by subunit composition (Lambert et al., 2001).
In particular, AP is a powerful modulator of GABA-A receptors containing δ subunits
(Adkins et al., 2001; Brown et al., 2002; Wohlfahrth et al., 2002), likely due to a primary
influence of this subunit in the transduction of neurosteroid signals (Hosie et al., 2009).
Accordingly, the lack of δ subunits has been shown to greatly reduce the sensitivity of
GABA-A receptor to neurosteroids (Mihalek et al., 1999). Our data showed that neither the
GABA-A receptor antagonist bicuculline nor the genetic deficiency of the δ subunit
modified the sensitivity of mice to the PPI-disrupting effects of D1 receptor stimulation.
Although these data challenge the idea that GABA-A receptors may play a key role in the
observed effects of AP, we cannot exclude that some specific families of these receptors and
other neurosteroids may still contribute to the dopaminergic modulation of PPI; in particular,
future studies will be needed to evaluate whether the role of AP in sensorimotor gating may
be modified by fluctuations in the levels of its 3β-epimer isoallopregnanolone (3β,5α,
tetrahydroprogesterone), which acts as an endogenous antagonist for the AP site within
GABA-A receptors.
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We also studied the potential implications of PXR in the role of AP on PPI deficits induced
by D1 receptor agonists. PXR is a promiscuous nuclear receptor involved in xenobiotic
metabolism and elimination (di Masi et al., 2009). While most studies on PXR have focused
on its role in the liver, this target is also present in the brain (Lamba et al., 2004) and is
implicated in the metabolism of cholesterol. AP is a well-known ligand of PXR, and some of
its biological actions can be attenuated by reducing the expression of this receptor (Frye et
al., 2014). It should be noted that PXR is also likely involved in the biosynthesis of AP (Frye
et al., 2014). However, PXR-deficient mice did not show any significant modification of the
PPI-disrupting effects of D1 receptor agonists.
These results suggest that other downstream mechanisms of AP are likely linked to the
sensitivity of mice to the effects of D1 receptor agonist on PPI. For example, the effects of
AP may be mediated by other receptors, such as NMDA glutamate receptors. AP sulfate has
been shown to exert a modest negative modulation of these receptors (Weaver et al., 2000).
Interestingly, previous data in our lab have shown that the actions of D1 agonists in
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decreasing PPI is facilitated and potentiated by low doses of NMDA antagonists (Bortolato
et al., 2005).
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Several limitations to this study should be acknowledged. First, we did not test female mice.
Prior testing in rats showed that the antidopaminergic effects of finasteride were preserved in
both males and females, as well as castrated males (Paba et al., 2011; Devoto et al., 2012).
Thus, we speculate that females may display the same effects as those observed in males;
however, this conclusion will need to be confirmed by future studies. Second, while our
analyses were limited to a few steroids, it is possible that other neuroactive steroids may
participate to some of the observed effects. Extensive research has indicated that neuroactive
steroids extensively interact with dopamine signaling to regulate a broad array of
physiological functions (Sanchez et al, 2010). For example, both progesterone and
testosterone alter dopamine release and turnover in rodents (Sanchez et al, 2010). Further
research is warranted to address how these interactions may contribute to the
pathophysiology of gating disorders.
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These limitations notwithstanding, the results of these studies strongly support a role for AP
in the mediation of dopamine induced PPI deficits and raise important questions for future
research on the balance between D1 and D2 receptors in the regulation of sensorimotor
gating mechanisms. As mentioned in the introduction PPI is impaired in several disorders,
including schizophrenia and TS and OCD; notably, the ability of drugs to restore PPI in
rodents treated with dopaminergic agonists has been shown to predict antipsychotic potency
(Swerdlow et al, 1994) or validate therapeutic efficacy for TS (Godar et al., 2014). In line
with this idea, it is worth noting that finasteride may have therapeutic effects for TS
(Bortolato et al., 2007; Muroni et al., 2011) and schizophrenia (Koethe et al., 2008). If
translationally valuable, our results may support the possibility that selective 5αR1
inhibitors could have therapeutic effects for these conditions, without some of the adverse
effects of finasteride, including low libido and depression (Traish et al., 2015). A highly
selective 5αR1 inhibitor, MK386, has been developed for clinical use (Schwartz et al., 1992;
Ellsworth et al., 1996) and shown to be safe and well-tolerated in Phase I and II clinical
trials. Future studies will be needed to evaluate whether selective 5αR1 inhibitors may have
effects akin to those elicited by finasteride in animal models of schizophrenia and TS.
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Highlights
•

5α-reductases (5αRs) catalyze the rate-limiting step of neurosteroid synthesis

•

In mice, D1 receptor agonists reduce the prepulse inhibition (PPI) of the
startle

•

5αR1 knockout mice are insensitive to PPI deficits caused by D1 receptor
activation

•

The PPI-disrupting properties of D1 agonists are reinstated by
allopregnanolone
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Fig. 1.

Author Manuscript

Responsiveness of 5αR1-deficient mice to the effects of D1 and D2 receptor agonists on
startle reflex and prepulse inhibition (PPI). Data are shown as means ± SEM. ^P<0.05,
^^^P<0.001 in comparison with wildtype (WT) mice (Main effect of genotype). ***P<0.001
vs vehicle (VEH)-treated WT mice (genotype x treatment interaction). #,P<0.05, ###P<0.001
vs WT mice treated with dopaminergic agonists (genotype x treatment interaction);
ooo,P<0.001 vs KO mice treated with VEH (genotype x treatment interaction). The number
of mice in each group is indicated. Abbreviations: HZ, 5αR1 heterozygous; KO, 5αR1
knockout; SKF, SKF 82958 (0.3 mg/kg, IP); QUIN, QUIN (0.5 mg/kg, IP).
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Fig. 2.

Locomotor responses to dopamine D1 and D2 agonists in 5αR1 knockout (KO) mice. Mice
were allowed to habituate to the force plate actometer for 60 minutes. At 60 minutes the
mice were briefly removed and injected with vehicle (VEH), SKF 82958 (SKF, 0.3mg/kg,
IP) or QUIN (QUIN, 0.5mg/kg, IP) and returned to the actometer. The responses of wild
type (WT) mice (A) and 5αR1 KO littermates (B) are described. Data are shown as mean ±
SEM. ***P<0.001 for comparisons between KO mice treated with either QUIN or vehicle at
10 min after injection. The number of mice in each group is indicated.
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Fig. 3.
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Responsiveness of 5αR2-deficient mice to the effects of D1 and D2 receptor agonists on
startle reflex and prepulse inhibition (PPI). Data are shown as means ± SEM. The number of
mice in each group is indicated. Abbreviations: WT, wildtype; HZ, 5αR1 heterozygous; KO,
5αR1 knockout; VEH, vehicle; SKF 82958 (SKF, 0.3 mg/kg, IP). QUIN, QUIN (0.5 mg/kg,
IP).
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Responsiveness of 5αR1 knockout (KO) mice to the effects of the D1 receptor agonist SKF
82958 (SKF; 0.3 mg/kg, IP) in combination with dihydroprogesterone (DHP, 3–10 mg/kg,
IP; A-B; n=8/group) and allopregnanolone (AP, 1–3 mg/kg, IP; C-D; n=12/group), on startle
reflex and prepulse inhibition (PPI). Data are shown as means ± SEM. ^^^, P<0.001 in
comparison with wild-type (WT) mice (Main effect of genotype); **, P<0.01, ***, P<0.001
in comparison with VEH-treated WT mice (genotype x SKF interaction). ooo, P<0.001 in
comparison with KO mice treated with SKF and vehicle (VEH) (genotype x SKF x AP
interaction).
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Fig. 5.
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Responsiveness of 5αR1 knockout (KO) mice to the effects of the D1 receptor agonist SKF
82958 (SKF; 0.3 mg/kg, IP) in combination with dihydrotestosterone (DHT; A-B), 5αandrostane-3α,17β-diol (3αOL; C-D), and androsterone (ASN, 3 mg/kg, IP; E-F) on startle
reflex and prepulse inhibition (PPI). N=12/group for all experiments. Data are shown as
means ± SEM. ^^^, P<0.001 in comparison with wild-type (WT) mice (Main effect of
genotype); ***, P<0.001 in comparison with VEH-treated WT mice (genotype x SKF
interaction).
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Fig. 6.
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Effects of the D1 receptor agonist SKF 82958 (SKF, 0.3 mg/kg, IP) on startle reflex and
prepulse inhibition (PPI), in combination with the GABA-A receptor antagonist bicuculline
(1 mg/kg, IP) (A-B), and in knockout (KO) mice for GABA-A δ-subunit (C-D) and
pregnane X receptor (PXR) (E-F). Data are shown as means ± SEM. The number of mice in
each group is indicated. Abbreviations: WT, wildtype; VEH, vehicle.
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